Published Paper Details:

API and a stoichiometric amount of a pharmaceutically approved co-crystal former are combined to generate co-crystals. Pharmaceutical Co-crystals are nonionic supramolecular complexes that can be employed in pharmaceutical development to solve physical property challenges such as solubility, stability, and bioavailability without affecting the chemical makeup of the API. A cocrystal is a crystalline entity generated by two or more molecular entities with weak intermolecular interactions such as hydrogen bonding and - stacking. Biodegradable hydrogel systems, super porous systems. Co-crystallization changes the molecular interactions and composition of medicinal materials and is thought to be a better option for optimising therapeutic characteristics. Co-crystals provide an alternative method in which any API with acidic, basic, or ionizable groups could potentially be co-crystallized. This aspect also contributes to the complementarity of existing approaches by reintroducing compounds with limited pharmacological profiles due to nonionizable functional groups. The article provides a brief overview of co-crystallization, how it differs from other states, and why it is important as an alternative to slat formation. The page also includes a summary of the numerous cocrystals that have been studied, emphasising their significance in the current trend of improving various physical, chemical, and medicinal properties.